▶ 調査レポート

多発性硬化症薬の世界市場:薬物クラス別(インターフェロンベータ、スフィンゴシン1リン酸受容体モジュレーター、混合ポリマー、NF-KB阻害剤、ピリミジン合成阻害剤、モノクローナル抗体、コルチコステロイド、副腎皮質刺激ホルモン、その他)、疾患種類別(再発寛解型MS(RRMS)、一次進行型MS(PPMS)、二次進行型MS(SPMS)、進行型再発MS(PRMS))、投与経路別(非経口、経口)、流通経路別(病院薬局、小売薬局・ドラッグストア、オンライン薬局)

• 英文タイトル:Multiple Sclerosis Drugs Market (Drug Class: Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-KB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others; Disease Type: Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), and Progressive-relapsing MS (PRMS); Route of Administration: Parenteral and Oral; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。多発性硬化症薬の世界市場:薬物クラス別(インターフェロンベータ、スフィンゴシン1リン酸受容体モジュレーター、混合ポリマー、NF-KB阻害剤、ピリミジン合成阻害剤、モノクローナル抗体、コルチコステロイド、副腎皮質刺激ホルモン、その他)、疾患種類別(再発寛解型MS(RRMS)、一次進行型MS(PPMS)、二次進行型MS(SPMS)、進行型再発MS(PRMS))、投与経路別(非経口、経口)、流通経路別(病院薬局、小売薬局・ドラッグストア、オンライン薬局) / Multiple Sclerosis Drugs Market (Drug Class: Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-KB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others; Disease Type: Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), and Progressive-relapsing MS (PRMS); Route of Administration: Parenteral and Oral; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / D0JU09096資料のイメージです。• レポートコード:D0JU09096
• 出版社/出版日:Transparency Market Research / 2020年1月21日
• レポート形態:英文、PDF、207ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Corporate License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、多発性硬化症薬の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬物クラス別(インターフェロンベータ、スフィンゴシン1リン酸受容体モジュレーター、混合ポリマー、NF-KB阻害剤、ピリミジン合成阻害剤、モノクローナル抗体、コルチコステロイド、副腎皮質刺激ホルモン、その他)分析、疾患種類別(再発寛解型MS(RRMS)、一次進行型MS(PPMS)、二次進行型MS(SPMS)、進行型再発MS(PRMS))分析、投与経路別(非経口、経口)分析、流通経路別(病院薬局、小売薬局・ドラッグストア、オンライン薬局)分析、地域別分析、競争状況などの構成でお届けいたします。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・多発性硬化症薬の世界市場:薬物クラス別(インターフェロンベータ、スフィンゴシン1リン酸受容体モジュレーター、混合ポリマー、NF-KB阻害剤、ピリミジン合成阻害剤、モノクローナル抗体、コルチコステロイド、副腎皮質刺激ホルモン、その他)
・多発性硬化症薬の世界市場:疾患種類別(再発寛解型MS(RRMS)、一次進行型MS(PPMS)、二次進行型MS(SPMS)、進行型再発MS(PRMS))
・多発性硬化症薬の世界市場:投与経路別(非経口、経口)
・多発性硬化症薬の世界市場:流通経路別(病院薬局、小売薬局・ドラッグストア、オンライン薬局)
・多発性硬化症薬の世界市場:地域別
・競争状況

Multiple Sclerosis Drugs Market – Scope of the Report

TMR’S report on the multiple sclerosis drugs market studies the past as well as the current growth trends and opportunities, to gain valuable insights of the same indicators for the market over the forecast period from 2019 to 2027. The report provides the overall market revenue of the multiple sclerosis drugs market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the multiple sclerosis drugs market for the forecast period 2019–2027.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the multiple sclerosis drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approach to study various phenomena in the multiple sclerosis drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the multiple sclerosis drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the multiple sclerosis drugs market.

The report also delves into the competitive landscape of the multiple sclerosis drugs market. Key players operating in the multiple sclerosis drugs market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the multiple sclerosis drugs market that have been profiled in this report.

Key Questions Answered in Multiple Sclerosis Drugs Market Report

How does the development of multiple sclerosis drugs provide the scope of growth in the multiple sclerosis drugs market?
How alliances and partnerships between players are widening the scope of new line of treatment for multiple sclerosis?
What are the revenue share projections of key segments under various criteria in the multiple sclerosis drugs market during the forecast period?
Which segment is likely to register leading revenue until the end of the forecast period in 2027?
How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall multiple sclerosis drugs market?
Multiple Sclerosis Drugs Market – Research Objectives and Research Approach

The comprehensive report on the multiple sclerosis drugs market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of line of treatment of multiple sclerosis.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the multiple sclerosis drugs market, in terms of drug class, disease type, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the multiple sclerosis drugs market.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Multiple Sclerosis Drugs Market

4. Market Overview

4.1. Introduction

4.1.1. Multiple Sclerosis Drugs Market Introduction

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Multiple Sclerosis Drugs Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Pipeline Analysis

5.2. Regulatory Scenario

5.3. Disease Epidemiology

5.4. Market Access Overview

5.5. Key Mergers & Acquisitions

6. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Drug Class, 2017–2027

6.3.1. Interferon Beta

6.3.2. Sphingosine 1 Phosphate Receptor Modulators

6.3.3. Mixed Polymers

6.3.4. NF-κB Inhibitor

6.3.5. Pyrimidine Synthesis Inhibitor

6.3.6. Monoclonal Antibodies

6.3.7. Corticosteroids

6.3.8. Adrenocorticotropic Hormone

6.3.9. Others

6.4. Market Attractiveness, by Drug Class

7. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Disease Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Disease Type, 2017–2027

7.3.1. Relapsing-remitting MS (RRMS)

7.3.2. Primary-progressive MS (PPMS)

7.3.3. Secondary-progressive MS (SPMS)

7.3.4. Progressive-relapsing MS (PRMS)

7.4. Market Attractiveness, by Disease Type

8. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Route of Administration, 2017–2027

8.3.1. Parenteral

8.3.2. Oral

8.4. Market Attractiveness by Route of Administration

9. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Market Value Forecast, by Distribution Channel, 2017–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies & Drug Stores

9.3.3. Online Pharmacies

9.4. Market Attractiveness, by Distribution Channel

10. Global Multiple Sclerosis Drugs Market Analysis and Forecast, by Region

10.1. Key Findings

10.2. Market Value Forecast, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Market Attractiveness, by Country/Region

11. North America Multiple Sclerosis Drugs Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Drug Class, 2017–2027

11.2.1. Interferon Beta

11.2.2. Sphingosine 1 Phosphate Receptor Modulators

11.2.3. Mixed Polymers

11.2.4. NF-κB Inhibitor

11.2.5. Pyrimidine Synthesis Inhibitor

11.2.6. Monoclonal Antibodies

11.2.7. Corticosteroids

11.2.8. Adrenocorticotropic Hormone

11.2.9. Others

11.3. Market Value Forecast, by Disease Type, 2017–2027

11.3.1. Relapsing-remitting MS (RRMS)

11.3.2. Primary-progressive MS (PPMS)

11.3.3. Secondary-progressive MS (SPMS)

11.3.4. Progressive-relapsing MS (PRMS)

11.4. Market Value Forecast, by Route of Administration, 2017–2027

11.4.1. Parenteral

11.4.2. Oral

11.5. Market Value Forecast, by Distribution Channel, 2017–2027

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies & Drug Stores

11.5.3. Online Pharmacies

11.6. Market Value Forecast, by Country, 2017–2027

11.6.1. U.S.

11.6.2. Canada

11.7. Market Attractiveness Analysis

11.7.1. By Drug Class

11.7.2. By Disease Type

11.7.3. By Route of Administration

11.7.4. By Distribution Channel

11.7.5. By Country

12. Europe Multiple Sclerosis Drugs Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Drug Class, 2017–2027

12.2.1. Interferon Beta

12.2.2. Sphingosine 1 Phosphate Receptor Modulators

12.2.3. Mixed Polymers

12.2.4. NF-κB Inhibitor

12.2.5. Pyrimidine Synthesis Inhibitor

12.2.6. Monoclonal Antibodies

12.2.7. Corticosteroids

12.2.8. Adrenocorticotropic Hormone

12.2.9. Others

12.3. Market Value Forecast, by Disease Type, 2017–2027

12.3.1. Relapsing-remitting MS (RRMS)

12.3.2. Primary-progressive MS (PPMS)

12.3.3. Secondary-progressive MS (SPMS)

12.3.4. Progressive-relapsing MS (PRMS)

12.4. Market Value Forecast, by Route of Administration, 2017–2027

12.4.1. Parenteral

12.4.2. Oral

12.5. Market Value Forecast, by Distribution Channel, 2017–2027

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies & Drug Stores

12.5.3. Online Pharmacies

12.6. Market Value Forecast, by Country/Sub-region, 2017–2027

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Italy

12.6.5. Spain

12.6.6. Rest of Europe

12.7. Market Attractiveness Analysis

12.7.1. By Drug Class

12.7.2. By Disease Type

12.7.3. By Route of Administration

12.7.4. By Distribution Channel

12.7.5. By Country/Sub-region

13. Asia Pacific Multiple Sclerosis Drugs Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Drug Class, 2017–2027

13.2.1. Interferon Beta

13.2.2. Sphingosine 1 Phosphate Receptor Modulators

13.2.3. Mixed Polymers

13.2.4. NF-κB Inhibitor

13.2.5. Pyrimidine Synthesis Inhibitor

13.2.6. Monoclonal Antibodies

13.2.7. Corticosteroids

13.2.8. Adrenocorticotropic Hormone

13.2.9. Others

13.3. Market Value Forecast, by Disease Type, 2017–2027

13.3.1. Relapsing-remitting MS (RRMS)

13.3.2. Primary-progressive MS (PPMS)

13.3.3. Secondary-progressive MS (SPMS)

13.3.4. Progressive-relapsing MS (PRMS)

13.4. Market Value Forecast, by Route of Administration, 2017–2027

13.4.1. Parenteral

13.4.2. Oral

13.5. Market Value Forecast, by Distribution Channel, 2017–2027

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies & Drug Stores

13.5.3. Online Pharmacies

13.6. Market Value Forecast, by Country/Sub-region, 2017–2027

13.6.1. China

13.6.2. India

13.6.3. Japan

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Market Attractiveness Analysis

13.7.1. By Drug Class

13.7.2. By Disease Type

13.7.3. By Route of Administration

13.7.4. By Distribution Channel

13.7.5. By Country/Sub-region

14. Latin America Multiple Sclerosis Drugs Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value Forecast, by Drug Class, 2017–2027

14.2.1. Interferon Beta

14.2.2. Sphingosine 1 Phosphate Receptor Modulators

14.2.3. Mixed Polymers

14.2.4. NF-κB Inhibitor

14.2.5. Pyrimidine Synthesis Inhibitor

14.2.6. Monoclonal Antibodies

14.2.7. Corticosteroids

14.2.8. Adrenocorticotropic Hormone

14.2.9. Others

14.3. Market Value Forecast, by Disease Type, 2017–2027

14.3.1. Relapsing-remitting MS (RRMS)

14.3.2. Primary-progressive MS (PPMS)

14.3.3. Secondary-progressive MS (SPMS)

14.3.4. Progressive-relapsing MS (PRMS)

14.4. Market Value Forecast, by Route of Administration, 2017–2027

14.4.1. Parenteral

14.4.2. Oral

14.5. Market Value Forecast, by Distribution Channel, 2017–2027

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies & Drug Stores

14.5.3. Online Pharmacies

14.6. Market Value Forecast, by Country/Sub-region, 2017–2027

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Market Attractiveness Analysis

14.7.1. By Drug Class

14.7.2. By Disease Type

14.7.3. By Route of Administration

14.7.4. By Distribution Channel

14.7.5. By Country/Sub-region

15. Middle East & Africa Multiple Sclerosis Drugs Market Analysis and Forecast

15.1. Introduction

15.1.1. Key Findings

15.2. Market Value Forecast, by Drug Class, 2017–2027

15.2.1. Interferon Beta

15.2.2. Sphingosine 1 Phosphate Receptor Modulators

15.2.3. Mixed Polymers

15.2.4. NF-κB Inhibitor

15.2.5. Pyrimidine Synthesis Inhibitor

15.2.6. Monoclonal Antibodies

15.2.7. Corticosteroids

15.2.8. Adrenocorticotropic Hormone

15.2.9. Others

15.3. Market Value Forecast, by Disease Type, 2017–2027

15.3.1. Relapsing-remitting MS (RRMS)

15.3.2. Primary-progressive MS (PPMS)

15.3.3. Secondary-progressive MS (SPMS)

15.3.4. Progressive-relapsing MS (PRMS)

15.4. Market Value Forecast, by Route of Administration, 2017–2027

15.4.1. Parenteral

15.4.2. Oral

15.5. Market Value Forecast, by Distribution Channel, 2017–2027

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies & Drug Stores

15.5.3. Online Pharmacies

15.6. Market Value Forecast, by Country/Sub-region, 2017–2027

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Market Attractiveness Analysis

15.7.1. By Drug Class

15.7.2. By Disease Type

15.7.3. By Route of Administration

15.7.4. By Distribution Channel

15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Share Analysis, by Company, 2018

16.2. Company Profiles

16.2.1. Bayer AG

16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.1.2. Financial Overview

16.2.1.3. Product Portfolio

16.2.1.4. SWOT Analysis

16.2.1.5. Strategic

16.2.2. Teva Pharmaceutical Industries Ltd.

16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.2.2. Financial Overview

16.2.2.3. Product Portfolio

16.2.2.4. SWOT Analysis

16.2.2.5. Strategic

16.2.3. Novartis AG

16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.3.2. Financial Overview

16.2.3.3. Product Portfolio

16.2.3.4. SWOT Analysis

16.2.3.5. Strategic

16.2.4. Sanofi

16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.4.2. Financial Overview

16.2.4.3. Product Portfolio

16.2.4.4. SWOT Analysis

16.2.4.5. Strategic

16.2.5. F. Hoffmann-La Roche Ltd.

16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.5.2. Financial Overview

16.2.5.3. Product Portfolio

16.2.5.4. SWOT Analysis

16.2.5.5. Strategic

16.2.6. Celgene Corporation

16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.6.2. Financial Overview

16.2.6.3. Product Portfolio

16.2.6.4. SWOT Analysis

16.2.6.5. Strategic

16.2.7. Acorda Therapeutics, Inc.

16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.7.2. Financial Overview

16.2.7.3. Product Portfolio

16.2.7.4. SWOT Analysis

16.2.7.5. Strategic

16.2.8. Biogen, Inc.

16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.8.2. Financial Overview

16.2.8.3. Product Portfolio

16.2.8.4. SWOT Analysis

16.2.8.5. Strategic

16.2.9. Actelion Pharmaceuticals (Johnson & Johnson)

16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.9.2. Financial Overview

16.2.9.3. Product Portfolio

16.2.9.4. SWOT Analysis

16.2.9.5. Strategic

16.2.10. EMD Serono (Merck KGaA)

16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.10.2. Financial Overview

16.2.10.3. Product Portfolio

16.2.10.4. SWOT Analysis

16.2.10.5. Strategic

16.2.11. AbbVie, Inc.

16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

16.2.11.2. Financial Overview

16.2.11.3. Product Portfolio

16.2.11.4. SWOT Analysis

16.2.11.5. Strategic

List of Tables

Table 01: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 02: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 03: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 04: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 05: Global Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 08: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 09: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 10: North America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 11: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 13: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 14: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 15: Europe Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 16: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 17: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 18: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 19: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 20: Asia Pacific Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 21: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 24: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 25: Latin America Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 26: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 27: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 28: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2017–2027

Table 29: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 30: Middle East & Africa Multiple Sclerosis Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027